Latest News
Natera and Angiex partner to assess AGX101 response using Signatera
27 August 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) announced on Thursday that it has entered into a collaboration with privately held biotech company Angiex Inc to assess treatment response to Angiex's investi...
AstraZeneca and Amgen report Tezspire met primary endpoints in Phase III EoE trial
27 August 2026 - Biopharmaceutical companies AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) and Amgen Inc (NASDAQ:AMGN) on Thursday reported positive results from the Phase III CROSSING trial showing that Tezspire (tezepelumab) delivered statisticall...
Oxcia receives EMA orphan designation for OXC-201 in idiopathic pulmonary fibrosis
27 August 2026 - Swedish clinical-stage biotech company Oxcia AB, which develops therapies targeting oxidative stress and DNA damage response pathways, announced on Thursday that the European Medicines Agency has made the decision to grant Orphan Dru...
ReviR Therapeutics' RTX-117 receives FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease
27 August 2026 - Clinical-stage biotechnology company ReviR Therapeutics announced on Wednesday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to RTX-117, the company's investigational oral s...
Graviton BioScience reports positive trial results for GV101 in chronic Graft versus Host Disease
27 August 2026 - Clinical-stage biotechnology company Graviton BioScience Corporation announced on Wednesday the publication of peer-reviewed data from a multicentre Phase Ib/II multi-dose, open-label clinical trial evaluating the safety, tolerabilit...